Polypharmacy in Youth Treated With Antipsychotics: Do Antidepressants or Stimulants Add to the Risk for Type 2 Diabetes?

This publication has 10 references indexed in Scilit:

• Concomitant Use of Atypical Antipsychotics With Other Psychotropic Medication Classes and the Risk of Type 2 Diabetes Mellitus
  Journal of the American Academy of Child & Adolescent Psychiatry, 2017
• Type 2 Diabetes Mellitus in Youth Exposed to Antipsychotics
  JAMA Psychiatry, 2016
• Treatment of Young People With Antipsychotic Medications in the United States
  JAMA Psychiatry, 2015
• Risk for Incident Diabetes Mellitus Following Initiation of Second-Generation Antipsychotics Among Medicaid-Enrolled Youths
  JAMA Pediatrics, 2015
• Do antipsychotics increase diabetes risk in children and adolescents?
  Expert Opinion on Drug Safety, 2014
• Antipsychotics and the Risk of Type 2 Diabetes Mellitus in Children and Youth
  JAMA Psychiatry, 2013
• Antipsychotic Medication Use Among Children and Risk of Diabetes Mellitus
  Pediatrics, 2011
• Metabolic and endocrine adverse effects of second-generation antipsychotics in children and adolescents: A systematic review of randomized, placebo controlled trials and guidelines for clinical practice
  European Psychiatry, 2011
• Cardiometabolic Risk of Second-Generation Antipsychotic Medications During First-Time Use in Children and Adolescents
  JAMA, 2009
• Olanzapine Versus Aripiprazole for the Treatment of Agitation in Acutely Ill Patients With Schizophrenia
  Journal of Clinical Psychopharmacology, 2008